SNN News and Press, Smith & Nephew SNATS Inc. From 02/21/23

Smith & Nephew ( NYSE: SNN ) stock rose ~6% on Tuesday after Q4 revenue grew and the company provided FY23 outlook. Q4 revenue grew 1.4% Y/Y to ~$1.37B. Revenue from Orthopaedics segment fell -0.4% Y/Y to $549M, while revenue from Sports Medicine & ENT grew +...

Smith & Nephew press release ( NYSE: SNN ): FY GAAP EPS of $0.26 misses by $0.14 . EPSA of $0.82. Revenue of $5.21B in-line (flat Y/Y). Cash generated from operations of $581M (2021: $1,048M) with trading cash flow of $444M. Outlook: For 2023, we are target...

Summary Globus and NuVasive agreed to merge in a deal that will see Globus acquire its spinal surgery rival for 0.75 shares of GMED per NUVA share (or $3.1B). Globus shares sold off sharply, as the Street clearly isn't sold on the advantages of the deal and/or Globus management's abilit...

Summary The Palm Valley Capital Fund invests in small cap stocks. While our Fund is new, its underlying absolute return-based investment strategy is not. We have practiced the same strategy throughout our careers in investment management. We do not believe U.S. stocks are pricing in an ...

Smith+Nephew receives Innovative Technology designation from Vizient for LEAF™ Patient Monitoring System PR Newswire Designation recognizes Vizient-contracted products that bring improvements to healthcare industry LONDON , Jan. 30, 2023 /PRNewswir...

Summary A micro cap health tech company following a path to large cap potential. A management team with vision, ownership, operational expertise, domain knowledge and that trust each other. They have a strong pipeline of 23 products and services with growing sales (124% year over ye...

Smith+Nephew expands procedural innovation with introduction of JOURNEY™ II ROX™ Total Knee Solution PR Newswire LONDON , Nov. 1, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces th...

Summary The Palm Valley Capital Fund invests in small cap stocks. While our Fund is new, its underlying absolute return-based investment strategy is not. We have practiced the same strategy throughout our careers in investment management. The combination of falling stock prices an...

Summary Smith & Nephew extends its downside in September and the question now turns to what value might be on offer. On closer inspection, there's been good reasoning behind the market's pricing of SNN this year. With contracting growth and forex headwinds still plaguing e...

Summary Medical devices manufacturer Smith & Nephew (S&N) has seen its shares sliding. I do not yet see the growth the company is targeting, but business has been recovering and its interim figures were decent if nothing special. Smith & Nephew's lack of clear grow...